Ultibro Breezhaler/

Ultibro Breezhaler combines indacaterol (an ultra-LABA) with glycopyrronium (a LAMA) for the maintenance treatment of COPD. Dual bronchodilation through two complementary mechanisms provides greater airflow improvement than either drug alone. Indacaterol has a rapid onset (within five minutes) and 24-hour duration, while glycopyrronium adds sustained muscarinic blockade. The Breezhaler device provides audible and visual feedback confirming correct inhalation.

How to Use Ultibro Breezhaler

Inhale one capsule once daily at the same time each day using the Breezhaler device. Place the capsule in the device, press the side buttons to pierce it, breathe out fully away from the mouthpiece, then inhale rapidly and deeply through the mouthpiece. A whirring sound confirms the dose is being released. Hold your breath briefly, then breathe out slowly.

Ultibro Breezhaler combines two long-acting bronchodilators (indacaterol and glycopyrronium) for COPD maintenance. It is not a rescue inhaler, always keep a short-acting reliever available for sudden breathlessness.

One capsule (85 mcg indacaterol / 43 mcg glycopyrronium) inhaled once daily. Do not swallow the capsule.

Common Side Effects

Common side effects include:

• Cough (often brief, at the time of inhalation)
• Nasopharyngitis
• Headache
• Upper respiratory tract infections
• Dry mouth

The cough that sometimes occurs with Ultibro Breezhaler is usually a brief tickle during inhalation and does not indicate the medication is harming your lungs. As a combination anticholinergic inhaler, it can occasionally cause urinary retention in men with an enlarged prostate. Seek medical advice if you experience difficulty urinating or sudden eye pain with visual disturbance.

Not for acute bronchospasm. Not recommended for asthma. Capsules must not be swallowed or used in other inhalers.

Contraindicated in known hypersensitivity to indacaterol, glycopyrronium, or any excipient.